Natanya Mishal
Neurology with Special Qualifications in Child Neurology · Miami, FLNPI 1275832032
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 394 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by UCB, Inc. at 27.3% of the total.
Across 394 payments — averaging $21.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$2K
- Jazz Pharmaceuticals Inc.$1K
- Neurelis, Inc.$998
- Greenwich Biosciences, Inc.$707
- Aquestive Therapeutics, Inc.$395
- SK Life Science, Inc.$393
- plus $2K from 25 others
Across 1 payment — averaging $228.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$228
What the payments were for
- Food & beverage$8,408100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 74 | $2,293 |
| Jazz Pharmaceuticals Inc. | 65 | $1,448 |
| Neurelis, Inc. | 65 | $998 |
| Greenwich Biosciences, Inc. | 33 | $707 |
| Aquestive Therapeutics, Inc. | 24 | $395 |
| SK Life Science, Inc. | 20 | $393 |
| Sunovion Pharmaceuticals Inc. | 18 | $360 |
| Sumitomo Pharma America, Inc. | 11 | $271 |
| Livanova USA, Inc. | 12 | $250 |
| Supernus Pharmaceuticals, Inc. | 17 | $218 |
| Ironshore Pharmaceuticals Inc. | 11 | $189 |
| Eisai Inc. | 6 | $102 |
| Zogenix Inc. | 4 | $93 |
| Novartis | 5 | $86 |
| Biogen | 4 | $80 |
| Immedica Pharma US, Inc. | 3 | $63 |
| Biocodex, Inc. | 1 | $59 |
| AstraZeneca | 2 | $49 |
| Acadia Pharmaceuticals Inc | 2 | $49 |
| Aucta Pharmaceuticals, Inc. | 2 | $47 |
| Corium, LLC | 2 | $43 |
| Azurity Pharmaceuticals, Inc. | 2 | $40 |
| Mallinckrodt Enterprises LLC | 2 | $39 |
| Catalyst Pharmaceuticals, Inc. | 2 | $39 |
| Saol Therapeutics Inc. | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Aprecia Pharmaceuticals, LLC | 1 | $15 |
| Piramal Critical Care | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| NS Pharma, Inc. | 1 | $12 |
| Vertical Pharmaceuticals, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VALTOCO$119
How this compares
$8,408 in reported general payments places this provider in the 65th percentile of 137 neurology with special qualifications in child neurology providers in Florida.
See all neurology with special qualifications in child neurology providers in Florida →
Other neurology with special qualifications in child neurology in Miami
- Trevor ResnickMiami$230K
- Migvis MonduyMiami$188K
- Elza VasconcellosMiami$170K
- Ian MillerMiami$104K
- Matt LallasMiami$88K
- Marytery FajardoMiami$44K
- Paula SchleiferMiami$31K
- Roberto Lopez-AlberolaMiami$31K
- Anuj JayakarMiami$24K
- Walter BradleyMiami$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.